Türk Kardiyoloji Derneği Koroner Arter Hastalığına Yaklaşım ve Tedavi Kılavuzu

 

Bu kılavuzu Türk Kardiyoloji Derneği Eksper Kurulu (alfabetik sırayla)

(Prof.Dr. Çetin Erol, Prof.Dr. Deniz Güzelsoy, Prof.Dr. Nevres Koylan,

Prof.Dr. Yılmaz Nişancı, Prof.Dr. Ahmet Oktay, Prof.Dr. Altan Onat,

Doç.Dr. Azmi Özler,Doç.Dr. Vedat Sansoy, Prof.Dr. İnan Soydan,

Doç.Dr. Oğuz Taşdemir,Prof.Dr. Lale Tokgözoğlu)

hazırlamıştır.

 

 

KAYNAKLAR

  1. Forrester JS, Merz NB, Bush TL, et al: Task Force 4. Efficacy of risk factor management. JACC 1996; 27: 991-1006.
  2. Onat A, Riskyük Çalışma Grubu adına: Korunma kılavuzu doğrultusunda çokmerkezli Riskyük çalışmasının ara sonuçları: hesaplanan kardiyovasküler olay riski %38 azaltılıyor. Türk Kardiyol Dern Arş 1998; 26: 392-407.
  3. Levy D, Wilson PWF, Anderson KM, Castelli WP: Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study. Am Heart J 1990; 119:712-7.
  4. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256:2823-8.
  5. The Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 365-74.
  6. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in mid-dle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-45.
  7. Superko HR, Krauss RM: Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994; 90: 1056-69.
  8. The 4S Investigators: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Study (4S). Lancet 1994; 344: 1383-9.
  9. Sacks FM, Pfeffer MA, Moye L, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
  10. White HD, Simes RJ, Watson J, et al: The LIPID Trial: Impact of lipid lowering therapy with pravastatin on the risk of stroke. JACC 1998;31:282A
  11. West of Scotland Coronary Prevention Group: West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348:1339-42.
  12. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279:1615-22.
  13. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-7.
  14. MacMahon S, Peto R, Cutler J, et al: Blood pressure, stroke and heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
  15. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke and coronary heart disease. Part 2. Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
  16. 15a.Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension: Guidelines for the Management of Hypertension. J Hypertension 1999; 17: 151-183.
  17. National Institutes of Health, National Heart, Lung and Blood Institute: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. NIH Publication No. 98-4080, 1997.
  18. Onat A, Şurdum-Avcı G, Soydan İ, Koylan N, Sansoy, V, Tokgözoğlu L: Türk erişkinlerinde kalp sağlığının dünü ve bugünü: TEKHARF çalışmasının sağladığı üç boyutlu harita. Kibele Tanıtım, İstanbul, 1996.
  19. Jonas MA, Oates JA, Ockene JK, Hennekens CH: Statement on smoking and cardiovascular disease for health care professionals. Circulation 1992; 86:1664-9.
  20. Simon DI, Ezratty AM, Loscalzo J: Lipoprotein(a) and atherothrombosis. Curr Opin Lipidol 1993;8:814-20.
  21. Blythe WB, Maddux FW: Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980-1986. Am J Kidney Dis 1991;18:33-7.
  22. Yan XC, Jing TY, Resnick LM, Phillips GB: Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993;13:467-71.
  23. Lam JY, Latour JG, Lesperance J, Waters D: Platelet aggregation, coronary artery disease progression and future coronary events. Am J Cardiol 1994;73:333-8.
  24. Onat A, Yıldırım B, Çetinkaya A ve ark: Erişkinlerimizde obezite ve santral obezite göstergeleri ve ilişkileri: 1990-98'de düşündürücü obezite artışı erkeklerde daha belirgin. Türk Kardiyol Dern Arş 1999; 27:209-17
  25. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-35.
  26. Stephens NG, Parsons A, Schofield PM, et al: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
  27. Onat A, Şurdum-Avcı G, Şenocak M ve ark: Türkiye'de Erişkinler Kalp Hastalığı ve Risk Faktörleri sıklığı taraması: 3. Kalp hastalıkları prevalansı. Türk Kardiyol Dern Arş 1991; 19:26-33.
  28. Haskell WL, Alderman EL, Fair JM, et al: Effects of intensive multiple risk factor reduction on coronary ath-erosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89: 975-90.
  29. Gordon T, Kannel WB: Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J 1982; 103: 1031-9.
  30. Assmann G, Schulte H: Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) Study. In: Assmann G (editor). Lipid metabolism disorders and coronary heart disease. München: MMV Medizin Verlag, 1989.
  31. Emond M, Mock MB, Davis KB, et al: Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation 1994; 90 2645-57.
  32. Pryor DB, Shaw LK, McCants CB, et al: Value of the history and physical examination in identifying patients at increased risk for coronary artery disease. Ann Intern Med 1993; 118: 81-90.
  33. Anderson KM, Wilson PWF, Odell PM, Kannel WB: An updated coronary risk profile: a statement for health professionals. Circulation 1991;83: 356-62.
  34. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
  35. Califf RM, Armstrong PW, Carver JR, D'Agostino RB Sr, Strauss WE: Task Force 5. Stratification of patients into high, medium, low risk subgroups for purposes of risk factor management. J Am Coll Card 1996; 27: 1007-19.
  36. Türk Kardiyoloji Derneği: Koroner Kalp Hastalığından Korunma ve Tedaviye İlişkin Ulusal Kılavuz. İstanbul, Türk Kardiyol Dern, 1995
  37. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D: Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society, and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31.
  38. Braunwald E, Mark DB, Jones RH, et al: Unstable Angina: Diagnosis and Management. Rockville (MD): Agency for Health Care Policy and Research, 1994.
  39. Gilpin EA, Koziol JA, Madsen EB, Henning H, Ross J Jr: Periods of differing mortality distribution during the first year after acute myocardial infarction. Am J Cardiol 1983; 52: 240-4.
  40. Smith LR, Harrell FE Jr, Rankin JS, et al: Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. Circulation 1991; 84: Suppl III:III245-53.
  41. Multicenter Post-Infarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 321-36.
  42. Morris KG: Use of radionuclide angiography following acute myocardial infarction. In: Califf RM, Mark DB, Wagner GS (eds). Acute Coronary Care. 2nd ed. St.Louis. Mosby-Year Book, 1995; 797-813.
  43. Mark DB, Nelson CL, Califf RM, et al: Continuing evaluation of therapy for coronary artery disease: initial results from the era of coronary angioplasty. Circulation 1994; 89: 2015-25.
  44. Yusuf S, Zucker D, Peduzzi P, et al: Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-70.
  45. Silver MT, Rose GA, Paul SD, O'Donnell CJ, O'Gara PT, Eagle KA: A clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Ann Intern Med 1994; 121: 750-6.
  46. Brunelli C, Cristofani R, L Abbate A for the OD1 Study Group: Long-term survival in medically treated patients with ischemic heart disease and prognostic importance of clinical and electrocardiographic data. (The Italian CNR Multicenter Study OD1). Eur Heart J 1989; 10: 292-303.
  47. Little WC, Constantinescu M, Applegate RJ, et al: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild to moderate coronary artery disease? Circulation 1988; 78: 1157-66
  48. Giroud D, Li JM, Urban P et al: Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992; 69:729-32.
  49. Kaski JC, Chen L, Chester M: Rapid angiographic progression of "target" and "non target" stenoses in patients awaiting coronary angioplasty. J Am Coll Cardiol 1995; 26:416-21
  50. Hammermeister KE, DeRouen TA, Hodge HT: Variables predictive of survival in patients with coronary disease, selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise arteriographic and quantitative angiographic evaluations. Circulation 1979; 59:421-30.
  51. European Coronary Surgery Study Group: Long-term results of a prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Lancet 1982; 2: 1173-80.
  52. Deckers JW, Rensing BJ. Simoons MK, Roelandt JRTC: Diagnostic merits of exercise testing in females. Eur Heart J 1989; 10: 543-50.
  53. American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Guidelines for clinical use of cardiac radionuclide imaging. J Am Coll Cardiol 1995; 25: 521-47
  54. Sawada SG, Segar DS, Ryan T, et al: Echocardiographic detection of coronary artery disease during dobutamine infusion. Circulation 1992; 82: 1605-14
  55. Diamond GA, Hirsch M, Forrester JS, et al: Application of information theory to clinical diagnostic testing. The electrocardiographic stress test. Circulation 1981; 63: 915-21
  56. Recommendations of the Task Force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18: 394-413
  57. American College of Cardiology / American Heart Association (ACC/AHA) Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Sub-committee on Coronary Angiography): Guidelines for coronary angiography. J Am Coll Cardiol 1987;10: 935-50
  58. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85
  59. Gruppo Italiano per lo Studio della Sopravivenza nell' Infarto Miocardio. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343; 1115-22
  60. Cohn PF: Pharmacological treatment of ischemic heart disease. Monotherapy vs combination therapy. Eur Heart J 1997; 18 (Suppl B) B27-B34.
  61. Cleland JGF, Walker A: Is medical treatment for angina the most cost-effective option? Eur Heart J 1997; 18: (Suppl B) B35-B42
  62. Jackson G: Stable angina: drugs, angioplasty or surgery. Eur Heart J 1997; 18: (Suppl B) B2 - B10
  63. Cerqueira MD: Diagnostic testing strategies for coronary artery disease. Special issues related to gender. Am J Cardiol 1995; 75: 52D - 60D
  64. Faxon DP: Coronary angioplasty for stable angina pectoris. In Beller, G.A. and Braunwald, E. (eds.) Chronic Ischemic Heart Disease, Atlas of Heart Disease, vol: 5, Philadelphia, Current Medicine, 1995, p. 9-16
  65. Ilia R, Kolansky D, Setaro J et al: Percutaneous transluminal coronary angioplasty in unstable and stable angina pectoris: a comparison of immediate success and complications. Cardiology 1992; 81: 245-50
  66. Parisi AF, Folland ED, Hartigan P: A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med 1992; 326: 10-6.
  67. Folland ED, Hartigan PM, Parisi AF: Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris. JACC 1997; 29: 1505-11.
  68. Hueb WA, Belloti G, de Oliveira SA, et al: The Medicine, Angioplasty, or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenosis. JACC 1995; 26: 1600-5.
  69. RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina; The second Randomized Interventional Treatment of Angina trial. Lancet 1997; 350: 461-8.
  70. Tu JV, Pashos CL, Naylor CD, et al: Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in Canada and the United States. N Engl J Med 1997; 336:1500-5
  71. Jaegere PP, Serruys PW: Clinical trials on intracoronary stenting. Thoraxcenter J 1996;8:40-4
  72. Macaya C, Serruys PW, Ruygrok P et al: Continued benefit of coronary stenting compared to balloon angioplasty: one-year clinical follow-up of Benestent trial. JACC 1996; 27: 255-61
  73. Erbel R, Haude M, Höpp HW et al: Randomized trial comparing stenting and balloon angioplasty for treatment of restenosis after balloon angioplasty. (abst.732-4). JACC 1996; 27: 139A
  74. Colombo A, Itoh A, Hall P, et al: Implantation of the Wallstent for diffuse lesions in native coronary arteries and venous bypass grafts without subsequent anticoagulation. JACC 1996; 27 (Suppl A): 53A
  75. Sirnes PA, Golf S, Myreng Y et al: Stenting in chronic coronary occlusions. (abst.732-5). JACC 1996; 27 (Suppl A): 139A
  76. Moussa I et al: Coronary stenting after rotational atherectomy in calcified and complex lesions. Eur Heart J 1996; Suppl. P2456
  77. Zampieri P, Colombo A, Almegor Y, Maiello L, Finci L: Results of coronary stenting of ostial lesions. Am J Cardiol 1994; 73: 901-3
  78. Wong SC, Baim DS, Schatz RA, et al: Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the Multicenter U.S. Palmaz-Schatz Stent experience. JACC 1995; 26: 704-12.
  79. Horntje J et al: Primary stenting for acute myocardial infarction: preliminary results of a randomised trial. Circulation 1996; Suppl 94: 3335
  80. Lytle BW, Cosgrove DM: Coronary artery bypass surgery. Curr Probl Surg 1992; 29:743.
  81. Peduzzi P, Detre K, Murphy M, et al: Ten-year incidence of myocardial infarction and prognosis after infarction: Veterans Administration Cooperative Study of Coronary Artery Surgery. Circulation 1991; 83: 747
  82. Alderman EL, Bourassa MF, Cohen LS, et al: Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. Circulation 1990; 82: 1629
  83. Kirklin JW, Akins CW, Blackstone EH, et al: Guidelines and indications for coronary artery bypass surgery. J Am Coll Cardiol 1991;17:543.
  84. Franco KL, Hammond GL: Surgical indications for coronary revascularization. In: Baue AE, Geha AS, Hammond GL et al (eds): Glenn's Thoracic and Cardiovascular Surgery (sixth ed). Stanford, Appleton & Lange, 1996.
  85. Grondin CM, Campeau L, Thornton JC, et al: Coronary artery bypass grafting with saphenous vein. Circulation 1989;79:124-9.
  86. Goldman S, Copeland J, Moritz T, et al: Internal mammary artery and saphenous vein graft patency. Effects of aspirin. Circulation 1990;82 (suppl IV): 237-42.
  87. Cameron A, Kemp HGJ, Green GE: Bypass surgery with the internal mammary artery graft: 15-year follow-up. Circulation 1986;74(suppl III): 30-6.
  88. Turina M: Coronary artery surgical technique. Curr Opin Cardiol 1993;8:916-26.
  89. Taşdemir O, Vural KM, Karagöz H, Bayazıt K: Coronary artery bypass grafting on the beating heart without the use of extracorporeal circulation. J Thorac Cardiovasc Surg 1998;116:69-73.
  90. Edwards FH, Clark RE, Schwartz M: Coronary artery bypass grafting: The Society of Thoracic Surgeons National Database Experience. Ann Thorac Surg 1994;57:12-9.
  91. Khan SS, Nessim S, Gray R et al: Increased mortality of women in coronary artery bypass surgery: evidence of referral bias. Ann Intern Med 1990;112:561-7
  92. Gersh BJ, Califf RM, Loop FD et al: Coronary bypass surgery in chronic stable angina. Circulation 1989;79:146-59.
  93. Aguirre FV, Younis LL, Chaitman BR et al: Early and 1-year clinical outcome of patients with evolving non-Q versus Q-wave myocardial infarction after thrombolysis: results from the TIMI II study. Circulation 1995;91:2541-8
  94. Zeraba W, Moss AJ, Raubertas RF: Risk of subsequent cardiac events in stable convalescing patients after first non Q-wave and Q-wave myocardial infarction. Coron Artery Dis 1994;5:1009-18.
  95. Braunwald E: Unstable angina: a classification. Circulation. 1989;80:410-4
  96. Braunwald E, Jones RH, Mark DM et al: Diagnosing and managing unstable angina. Circulation. 1994;90:613-22
  97. Theroux P, Fuster V: Acute coronary syndromes. Circulation 1998;97:1195-206
  98. Burke AP, Farb A, Malcolm GT et al: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. New Eng J Med 1997;336:1276-81
  99. Fuster V, Lewis A: Conner Memorial Lecture: Mech-anism leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-46
  100. Maseri A, L'Abbate A, Baroldi G et al: Coronary vasospasm as a possible cause of myocardial infarction: a conclusion derived from the study of 'preinfarction' angina. N Eng J Med 1978;299:1271-7.
  101. Cairns J, Theroux P, Armstrong P et al: Unstable angina: report from a Canadian expert roundtable. Can J Cardiol 1996;12:1279-92
  102. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease. Lancet. 1990;336:827-30
  103. Theroux P, for the PRISM-PLUS Investigators: Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms. American College of Cardiology Scientific Sessions, Anaheim, Calif, March 17, 1997
  104. Califf R, for the PURSUIT Investigators: Platelet IIb/IIIa in Unstable Angina: Receptor suppression using Integrilin trial (PURSUIT). European Meeting of Cardiology, Stockholm, August 25, 1997
  105. Cohen M, Adams PC, Parry G, et al: Combination antithrombotic therapy in unstable rest angina and non Q-wave infarction in nonprior aspirin versus aspirin users. Circulation 1994;89:81-8
  106. Oler S, Whooley MA, Oler J, et al: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA. 1996;276:811-5
  107. Cohen M, Demers C, Gurfinkel EP et al: Low molecular weight heparin versus unfractionated heparin for unstable angina and non Q- wave myocardial infarction. N Eng J Med 1997;337:447-52
  108. Muhlestein JB, Hammond EH, Carlsquist JF, et al: Increased incidence of Chlamidia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol. 1996;27:1555-61
  109. Gurfinkel E, Bozovich G, Daroca A, et al: Randomized trial of roxithromycin in non Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7
  110. Stone GW, Brodie BR, Griffin JJ, et al: Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. JACC 1998;31:23-30
  111. Ambrose J, Almeida O, Sharma S, et al: Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA trial. Circulation 1994;90:69-77
  112. Hultgren HN, Pfeifer JF, Anfel WW et al: Unstable angina: comparison of medical and surgical patients. Am J Cardiol 1977;39:734-40
  113. Luchi RJ, Scott SM, Dupree RH et al: Comparison of medical and surgical treatment for unstable angina pectoris. N Eng J Med 1987;316:977-84
  114. TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation 1994;89:1545-56
  115. Boden WE, O'Rourke RA, Crawford MH et al for the VANQWISH Trial Investigators: Outcomes in patients with acute non Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Eng J Med 1998; 338: 1785-92.
  116. Madsen JK, Grande P, Saunamaki K, et al: Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). Circulation 1997; 96: 748-55
  117. Szatmary LJ, Marco J, Fajadet J, et al: The combined use of diastolic counterpulsation and coronary dilatation in unstable angina due to multivessel disease under unstable angina hemodynamic conditions. Int J Cardiol 1988;19:59-66
  118. Smith HC, Gersh BJ: Indications for revascularization. L. Henry Edmunds, JR, (Ed) Cardiac Surgery in the Adult, USA: Mc Graw-Hill Co, 1997: 452-7
  119. Scott SM, Dupree, RH, Sharma GVRK, Luchi RJ: Associates of the VA Cooperative Study of Unstable Angina : VA Study of Unstable Angina. Circulation 1994; 90(part2): II 120-3
  120. Bertolasi CA, Tronge JE, Riccitelli MA, et al: Natural history of unstable angina with medical or surgical therapy. Chest 1976; 70: 596-9.
  121. National Cooperative Study Group: Unstable Angina Pectoris: National cooperative study group to compare surgical and medical therapy: II. In-hospital experience and initial follow-up results in patients with one-, two- and three-vessel disease. Am J Cardiol 1978; 42: 839
  122. Louagie YA, Jamart J, Buche M, et al: Operation for unstable angina pectoris: Factors influencing adverse in-hospital outcome. Ann Thorac Surg 1995, 59; 5: 1141-9
  123. Jönsson B: Measurement of health outcome and associated costs in cardiovascular disease. Eur Heart J 1996:17:2-7.
  124. Goldman L, Garber AM, Grover SA, Hlatky MA: Task Force 6. Cost effectiveness of assessment and management of risk factors. JACC 1996;27:964-1047.
  125. Goldman L, Weinstein MC, Goldman PA, Williams LW: Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265: 1145-51.
  126. Abbott RD, McGee D, Kannel WB, Wolf PA, Garrison RJ: The probabilitiy of developing certain cardiovascular disease in eight years at specified values of some characteristics. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. 87-2nd ed. Bethesda (MD): US Dept. of Health, Education and Welfare; 1987, Section 37. Publications NIH 87:2284.
  127. Szucs TD: Interpreting the results of economic studies across countries - Pitfalls and oportunities. In abstract book of 66th Congress of the European Atherosclerosis Society, Florence, July 13-17, 1996, p:12.
  128. Swan JC, Gersh BJ, Graboys TB, Ullyot DJ: Task Force 7. Evaluation and management of risk factors for the individual patient (Case management). J Am Coll Cardiol 1996; 27: 1030-9
  129. Ockene IS, Houston Miller N: Cigarette smoking, cardiovascular disease and stroke. A statement for health-care professionals from the American Heart Association. Circulation 1997; 96: 3243-7
  130. Curfman GD: Is exercise beneficial or hazardous to your heart? N Engl J Med 1993;329:1730-1
  131. Schuler G, Hambrecht R, Schlierf G, et al: Regular physical activity and low fat diet. Effects on progression of coronary artery disease. Circulation 1992; 86: 1-11
  132. Fletcher GF: How to implement physical activity in primary and secondary prevention. A statement for health- care professionals from the Task Force on Risk Reduction, American Heart Association. Circulation 1997; 96: 355-7
  133. Nicolosi R; Becker D, Elmer P, et al: AHA Medical/Scientific Statement. American Heart Association Guidelines for Weight Management Programs for Healthy Adults. Heart Dis Stroke 1994; 3: 221-8
  134. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP II). JAMA 1993; 269: 3015-23
  135. Smith SC, Blair SN, Criqui MH, et al: Preventing heart attack and death in patients with coronary disease. Circulation 1995; 92: 2-4
  136. Hennekens CH, Albert CM, Godfried SL, et al: Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med 1996; 335: 1660-7
  137. Smith SC Jr, Blair SN, Criqui MH, et al, for the Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. J Am Coll Cardiol 1995; 26: 292-4
  138. Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31
  139. Ryan TJ, Anderson JL, Antman EM, et al: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328-428
  140. Pearson T, Rapaport E, Criqui M, et al: Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association Writing Group. Circulation 1994; 90: 3125-33
  141. Pfeffer MA, Braunwald E, Moye LA, et al, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77
  142. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8
  143. Coronary Artery Surgery Study Group: Coronary Artery Surgery Study. Circulation 1983;68:951-60
  144. Vogel RA: Risk factor intervention and coronary artery disease: Clinical strategies. Coronary Artery Dis 1995; 6: 466- 71
  145. EUROASPIRE Study Group: EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82.
  146. Pearson TA, McBride PE, Miller NH, Smith SC: Task Force 8. Organization of preventive cardiology service. J Am Coll Cardiol 1996; 27: 1039-47
  147. Kottke TE, Blackburn H, Brekke ML, Solberg LI: The systematic practice of preventive cardiology. Am J Cardiol 1987; 59: 690-4